$GH

Hidalgo Medina Manuel sold $279K of GH

Hidalgo Medina Manuel sold 1,700 shares of Guardant Health, Inc. (GH) at an average of $164.24 ($163.94–$164.61, $0.28M total) across 2 trades on 2026-08-05.

Original reporting
SEC EDGAR · Hidalgo Medina Manuel
Published Aug 6, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 10:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest information is the specific open-market sale size, price range, and post-transaction holdings, which can influence short-term sentiment but lacks fundamental context.

02

Market read

Traders may monitor insider selling as a sentiment input, but this disclosure alone does not provide a new operational or financial catalyst.

03

What to watch

The filing does not state the director’s rationale, tax considerations, or whether other planned sales occurred; without those, the signal-to-noise is low.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-08-06 after-hours, reflecting insider sale disclosed today

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Hidalgo Medina Manuel sold 1,700 shares in open-market trades for about $279.2K, per a new Form 4 filed today.

Expected impact

Near-term impact is likely limited, though it can add modest sell-side optics if the market is sensitive to insider behavior.

Evidence & confidence

The disclosure is primary-source (Form 4) and time-stamped, but the article provides no accompanying company-specific negative news, guidance change, or material event.

Market effects

Minimal, as the event is an individual insider transaction without sector-wide regulatory or clinical implications.

None indicated; this is a US-listed company insider sale disclosure.

None indicated.

Counterpoint

Because the sale is not tied to a stated 10b5-1 plan, some traders may over-interpret it as a signal, even though director sales are often liquidity-driven.

Key entities

  • Guardant Health, Inc.

    US-listed company (GH) whose director reported an open-market sale of shares via Form 4.

  • Hidalgo Medina Manuel

    Director who sold 1,700 shares across two trades at about $163.945 to $164.605 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.